glp 1 and gip mechanism of action The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect Frontiers | Mechanisms of action
Description
Tirzepatide has shown superior effects in controlling blood sugar levels as well as in promoting weight loss in clinical trials
Some patients may choose to lower their dose to see if they can maintain their weight at a reduced strength
Typically administered as weekly subcutaneous injections, GLP-1 agonists can be injected into areas with fat just beneath the skin, such as the abdomen or back of the arms
10.1172/jci142243 121 TomitaT
Reduces appetite
It also provides 100% of your daily vitamins D, B9, and B12 needs
